

Hikma Ventures invests in biotechnology company BioSapien Inc., developer of a patented drug-delivery device intended to reduce the system-wide side effects of chemotherapy treatments

London, November 11, 2021 – Hikma Pharmaceuticals PLC announces that its venture capital arm, [Hikma Ventures](#), has participated in a seed financing round for [BioSapien Inc.](#), a venture-backed biotechnology company focused on innovative therapies to transform patient care.

BioSapien is a developer of 3D-printed biodegradable implantable devices intended to deliver FDA-approved drugs directly to cancerous cells. The company's device, MediChip®, is a novel 3D-printed biodegradable mesh that is intended to allow for chemotherapy to be delivered intravenously through a controlled drug release, with the aim of enabling physicians to reduce harmful side-effects and costs.

"As so many have witnessed or experienced first-hand, the effects of chemotherapy can take a tremendous toll on the immune system and body of patients undergoing treatment for cancer. We are excited to be an early investor in BioSapien and their novel drug delivery system, which has the potential to revolutionize the delivery of chemotherapy through a targeted, personalized, and controlled approach to alleviate the unwanted side effects and toxicities of the treatment." said Hamzeh Abdul-Hadi, Principal at Hikma Ventures. "We are also strong supporters of BioSapien's leadership team, led by CEO and Co-Founder Dr. Khatija Ali, and are proud to continue supporting female founders, who now comprise more than 20% of our investment portfolio."

"Hikma Ventures is a strong addition to our investor syndicate and we are extremely pleased to have such an experienced partner supporting our work to transform patient care," said Dr. Khatija Ali, CEO and Co-Founder of BioSapien. "The seed round funds will advance development of MediChip® and give access to global distribution channels and manufacturing."

-- ENDS --

Investor Enquiries

Hikma Ventures

Lana Ghanem
Managing Director, Hikma Ventures

lana@hikmaventures.com
+962 6 580 3100

Media Enquiries

Steve Weiss
David Belian
US Communications and Public Affairs

+1 732 788 8279
+1 848 254 4875
uscommunications@hikma.com

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/stable Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

**About Hikma Ventures**

Founded in August 2015, Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals. Hikma Ventures invests in global start-ups where Hikma's expertise can accelerate revenue growth and enhance value creation by providing ventures with access to the resources of a multinational pharmaceutical company. For more information, please visit www.hikmaventures.com.